NAFDAC Orders For Production Of Chloroquine For Treatment Of Covid-19
It has been public knowledge for a long time now that the use of chloroquine for the treatment of malaria has been discontinued. This is because malaria parasites are now resistant to chloroquine in some cases and so works to cure malaria in only a few people. However, with talk of it being a possible treatment for COVID-19, NAFDAC reportedly orders for chloroquine manufacturing to be kept in stock.
NAFDAC orders for the manufacturing of chloroquine
Chloroquine was developed in the 1940s and was used to treat malaria until other antimalarial drugs were developed. Since then chloroquine and others have been used in the treatment of other conditions like HIV, arthritis and then recently a likely addition in COVID-19.
According to a statement by the Director-General of NAFDAC Prof. Mojisola Adeyeye, the agency has contacted May and Baker, a Nigerian pharmaceutical company, for the production of chloroquine. The director said that the company had produced a series of drugs for an emergency stock for the treatment of COVID-19.
“About four weeks ago, I approached a local manufacturing company (May and Baker), a member of Pharmaceutical Manufacturing Group of Manufacturing Association of Nigeria (PMGMAN),” she said. “The company, whose flagship product in the past was Chloroquine, has produced a batch of the drug for emergency stock.”
Speaking further, she said the company already had NAFDAC approval for the production of chloroquine years ago before its discontinuation. Although at first, the company’s managing director expressed some difficulty in getting the API.
“He called shortly after that he was able to get the API and was asked to manufacture a batch for the emergency stock, just in case more people become exposed and infected with the virus.
“The batch has been manufactured, and the company plans to make more batches if needed,” she said.
However, she advised the public to avoid the usage of chloroquine without the supervision of a medical doctor. She said that the agency would ensure strict compliance of the clinical trial protocol guidelines through its regulatory activities.
If anyone is feeling unwell and showing COVID-19 symptoms of fever, dry cough, and shortness of breath, please go to the nearest hospital or call the following emergency numbers: 08023169485, 08033565529, 08052817243 and 08023401214.
Source: 1st News